NCT04309578 2026-04-03
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Completed
Clinical Trials
173 trialsNCT00420563 2026-03-16
PAL-ANGI
Centre Oscar Lambret
Phase 2 Completed
NCT05148078 2026-03-02
Pediatric Radiation Oncology With Movie Induced Sedation Effect (PROMISE)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT03697304 2026-01-27
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
Boehringer Ingelheim
Phase 2 Completed
NCT03752333 2026-01-22
CUPem
Imperial College London
Phase 2 Completed
NCT07335237 2026-01-13
Clinical Study on the Prevention and Treatment of Postoperative Gastrointestinal Dysfunction by Acupuncture Under ERAS Management Based on Artificial Intelligence Monitoring
Jiangsu Province Hospital of Traditional Chinese Medicine
Phase 2 Completed
NCT01771458 2025-11-24
SHIVA
Institut Curie
Phase 2 Completed
NCT03498521 2025-11-19
CUPISCO
Hoffmann-La Roche
Phase 2 Completed
NCT04819373 2025-11-12
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
Eikon Therapeutics
Phase 2 Completed
NCT03652493 2025-10-06
PRO-CARBO
Centre Francois Baclesse
Phase 2 Completed
NCT03755895 2025-10-03
HYCUDES
Institut de Cancérologie de Lorraine
Phase 2 Completed
NCT02843165 2025-09-30
Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease
University of California, San Diego
Phase 2 Completed
NCT01979393 2025-08-01
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT06926673 2025-07-03
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
GlaxoSmithKline
Phase 2 Completed
NCT00505063 2025-06-15
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03570619 2025-05-08
IMPACT
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT03406650 2025-05-04
SAKK 06/17
Swiss Cancer Institute
Phase 2 Completed
NCT03314324 2025-04-17
ODENZA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT05217069 2025-04-16
FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC
Ludwig-Maximilians - University of Munich
Phase 2 Completed
NCT05673811 2025-04-16
VIRAGE
Theriva Biologics SL
Phase 2 Completed
NCT04014075 2025-04-03
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
Daiichi Sankyo
Phase 2 Completed
NCT06083662 2025-03-18
Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers
Korea University Guro Hospital
Phase 2 Completed
NCT04187833 2025-01-14
Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03719924 2025-01-08
OESIRI
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT04551521 2025-01-08
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Phase 2 Completed
NCT05663801 2024-12-27
Magnesium Sulphate Versus Ketamine as an Adjuvant to Bupivacaine in Pectoral Nerve Block During Mastectomy
Beni-Suef University
Phase 2 Completed
NCT01650194 2024-12-10
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients
Astellas Pharma Inc
Phase 2 Completed
NCT03760081 2024-11-13
A Study to Assess the Safety and Efficacy of ASP1650, a Monoclonal Antibody Targeting Claudin 6 (CLDN6), in Male Subjects With Incurable Platinum Refractory Germ Cell Tumors
Astellas Pharma Inc
Phase 2 Completed
NCT04065139 2024-09-19
PIPAC EstoK 01
Assistance Publique - Hôpitaux de Paris
Phase 2 Completed
NCT03094286 2024-06-24
Durvalumab in HIV-1 Patients With Solid Tumors
Spanish Lung Cancer Group
Phase 2 Completed
NCT04193553 2024-06-18
LENVAGIST
Centre Leon Berard
Phase 2 Completed
NCT02640508 2024-05-09
Eribulin and Lenvatinib in Advanced Solid Tumors
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT05160051 2024-04-12
68Ga-FAPI-46 PET for Imaging of FAP Expressing Cancer
University Hospital, Essen
Phase 2 Completed
NCT04410653 2024-04-05
Afatinib in Advanced NRG1-Rearranged Malignancies
German Cancer Research Center
Phase 2 Completed
NCT02034981 2024-02-28
AcSé
UNICANCER
Phase 2 Completed
NCT06238752 2024-02-02
RENMIN-213
Renmin Hospital of Wuhan University
Phase 2 Completed
NCT03891238 2024-02-01
ARIES
Consorzio Oncotech
Phase 2 Completed
NCT02607202 2024-01-26
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
Phase 2 Completed
NCT04508400 2024-01-09
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
Sun Yat-sen University
Phase 2 Completed
NCT00375830 2023-12-12
Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases
Stanford University
Phase 2 Completed
NCT00755898 2023-11-30
Urinary Excretion of Acetylamantadine by Cancer Patients
University of Manitoba
Phase 2 Completed
NCT03308942 2023-10-16
Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants
Tesaro, Inc.
Phase 2 Completed
NCT00579423 2023-10-05
Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04259658 2023-10-03
CAEP-B
Zealand University Hospital
Phase 2 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT00176267 2023-06-01
Paclitaxel, Carboplatin And Low Dose Radiation As Induction Therapy In Locally Advanced Head And Neck Cancer
University of Kentucky
Phase 2 Completed
NCT01746225 2023-06-01
SNAP
ETOP IBCSG Partners Foundation
Phase 2 Completed